Literature DB >> 8350329

Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial.

M E Weinblatt1, A L Maier, J S Coblyn.   

Abstract

OBJECTIVE: To determine if simultaneously administered low dose leucovorin interferes with the efficacy of methotrexate (MTX).
METHODS: An 8-week double blind placebo controlled study of leucovorin (1 mg) in 16 patients with rheumatoid arthritis receiving chronic MTX was performed at a single academic center.
RESULTS: A flare of disease activity was not observed. Clinical variables of arthritis activity did not change in the leucovorin treated population.
CONCLUSIONS: Low dose leucovorin when taken simultaneously with MTX did not interfere with the efficacy of MTX in a short term 8 week trial.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8350329

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  15 in total

1.  [Reducing toxicity of methotrexate with folic acid].

Authors:  P Harten
Journal:  Z Rheumatol       Date:  2005-06       Impact factor: 1.372

Review 2.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

3.  The frequency and clinical characteristics of methotrexate (MTX) oral toxicity in rheumatoid arthritis (RA): a masked and controlled study.

Authors:  A Ince; Y Yazici; V Hamuryudan; H Yazici
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

Review 4.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 5.  Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review.

Authors:  Susan M Goodman; Bruce N Cronstein; Vivian P Bykerk
Journal:  Clin Exp Rheumatol       Date:  2014-12-23       Impact factor: 4.473

6.  Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis.

Authors:  C J Haagsma; H J Blom; P L van Riel; M A van't Hof; B A Giesendorf; D van Oppenraaij-Emmerzaal; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1999-02       Impact factor: 19.103

Review 7.  Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases.

Authors:  Jirí Grim; Jaroslav Chládek; Jirina Martínková
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 8.  Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives?

Authors:  Alexandros Drosos
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis.

Authors:  M Hoekstra; A E van Ede; C J Haagsma; M A F J van de Laar; T W J Huizinga; M W M Kruijsen; R F J M Laan
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

Review 10.  Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.

Authors:  Emilio G Quetglas; Zlatan Mujagic; Simone Wigge; Daniel Keszthelyi; Sebastian Wachten; Ad Masclee; Walter Reinisch
Journal:  World J Gastroenterol       Date:  2015-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.